Biopharma company Spectrum Pharmaceuticals were crashing on Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer (NSCLC) had missed its main goal. The stock saw a drop of over 57%, marking it one of the worst performances for shares in 17 years. The move was the second-biggest, one-day … Continue reading “Spectrum Pharmaceuticals Sees its Worst Day in 17 Years”
Tag: Spectrum Pharmaceuticals
Biotech & Pharma
This Common Cancer Treatment May Disappear
It makes absolutely no sense for an effective cancer treatment to vanish from the market,…
June 16, 2016